VIR FY2025 SEC EDGAR DEF 14A #115 of 168 in industry

Vir Biotechnology, Inc. CEO pay ratio

The CEO earned $7.9M in FY2025 against median worker pay of $331,187 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
DE
Filing date
2026-04-16
Industry
Chemicals & Pharmaceuticals
Industry rank
#115/168

Data updated August 2026

Subscribe to Vir Biotechnology, Inc. CEO pay filing updates (RSS)

CEO-to-worker pay ratio
24:1
Below Average (Scale: 0–1000:1)
CEO pay
$7.9M
Median worker
$331,187

Answer first

Vir Biotechnology, Inc.'s FY2025 CEO total of $7.9M ranks #688 of 1,423 complete filings; its 24:1 pay ratio ranks #1179. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $331,187. Industry placement uses the FY2025 SIC-28 peer cohort (# 115 of 168, 32nd percentile - below the industry median pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#688
$7.9M of 1,423 FY2025
Ratio rank
#1179
24:1 of 1,423
Industry pct
32nd
below the industry median pay ratio

How Vir Biotechnology, Inc. ranks nationally

Vir Biotechnology, Inc. CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$7,948,488 Top 48% higher than 52% of 1,423 companies

$0–$2,500,000: 304 companies (21%). Below this entry. $2,500,000–$5,000,000: 182 companies (13%). Below this entry. $5,000,000–$7,500,000: 208 companies (15%). Below this entry. $7,500,000–$10,000,000: 192 companies (13%). This entry sits in this band. $10,000,000–$12,500,000: 139 companies (10%). Above this entry. $12,500,000–$15,000,000: 91 companies (6%). Above this entry. $15,000,000–$17,500,000: 88 companies (6%). Above this entry. $17,500,000–$20,000,000: 54 companies (4%). Above this entry. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Vir Biotechnology, Inc. vs. Chemicals & Pharmaceuticals peers

CEO total pay ($7.9M) against pay ratio (24:1) for Vir Biotechnology, Inc. (marked) and its 5 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both1847343.64098121.863489008599678.210850456.422.1:127.3:132.5:137.7:143.0:1CEO total payPay ratio (CEO : median worker)Vir Biotechnology, Inc., CEO total pay: 7948488 · Pay ratio (CEO : median worker): 24:1Vir Biotechnology, Inc.Mirum Pharmaceuticals, Inc., CEO total pay: 10441224 · Pay ratio (CEO : median worker): 24:1Mirum Pharmaceuticals, Inc.Siga Technologies Inc, CEO total pay: 3202425 · Pay ratio (CEO : median worker): 25:1Siga Technologies IncKronos Worldwide Inc, CEO total pay: 2256576 · Pay ratio (CEO : median worker): 23:1Kronos Worldwide IncArdelyx, Inc., CEO total pay: 7796171 · Pay ratio (CEO : median worker): 25:1Ardelyx, Inc.Travere Therapeutics, Inc., CEO total pay: 8457151 · Pay ratio (CEO : median worker): 23:1Travere Therapeutics, Inc.
Vir Biotechnology, Inc. vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Vir Biotechnology, Inc.'s structured SEC pay-ratio disclosure. See our methodology →

Filing-year trail · Vir Biotechnology, Inc.

Complete DEF 14A pay-ratio filings for this CIK across FY2021–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).

Latest ratio
24:1
FY2025
vs prior FY
-4:1
from FY2024 28:1
CEO $ YoY
-14%
$7.9M latest
Filings shown
5
FY2021–2025
Vir Biotechnology, Inc. CEO total compensation, median worker pay, and pay ratio by fiscal year from SEC EDGAR DEF 14A.
FY CEO pay Δ pay Median worker Pay ratio Δ ratio
2021 $20.9M - $402,518 52:1 -
2022 $7.4M -65% $230,835 32:1 -20:1
2023 $39.5M +435% $301,437 131:1 +99:1
2024 $9.2M -77% $328,725 28:1 -103:1
2025 $7.9M -14% $331,187 24:1 -4:1

Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1706431, FY2021–2025. Adjacent-year deltas only.

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
24:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$7.9M
Companies in Industry
168
vs. Industry Median
Below
#115 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Vir Biotechnology, Inc.: near-parity Item 402(u) ratio

Vir Biotechnology, Inc.'s FY2025 ratio 24:1 ranks #115 of 168 Chemicals & Pharmaceuticals filers (32nd percentile). the CEO earned 24× the median employee ($331,187) in FY2025.

At $331,187 median worker pay, the FLOOR stamp is near pay-parity territory under HEAVY CEO total.

CEO Total Pay

$7.9M

FY2025 Summary Compensation, near median

Pay Ratio

24:1

Below typical

Vir Biotechnology, Inc. in the lower Chemicals & Pharmaceuticals third

Vir Biotechnology, Inc.'s FY2025 ratio 24:1 ranks #115 of 168 Chemicals & Pharmaceuticals filers (32nd percentile). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Vir Biotechnology, Inc.'s $7.9M CEO total is above the $7.9M industry median CEO pay.

Dollar rank #688 and ratio rank #1179 split - treat 24:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$7.9M
Median Employee Pay
$331,187
Pay Ratio
24:1
Filing Date
2026-04-16

Company Info

Ticker
VIR
CIK
1706431
Industry
Chemicals & Pharmaceuticals
SIC Code
2836
State
DE
View SEC filings →
SEC EDGAR DEF 14A for CIK 1706431, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Vir Biotechnology, Inc.'s FY2025 ratio 24:1 ranks #115 of 168 Chemicals & Pharmaceuticals filers (32nd percentile).

Read with Vir Biotechnology, Inc.

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps FLOOR · HEAVY · ELITE-MED.

Cavco Industries, Inc. · HEAVY

ABS(ceo_total_comp) peer at $8.0M (Δ $13K heavier vs Vir Biotechnology, Inc.); MID · PAR-MED vs this page's FLOOR · HEAVY · ELITE-MED.
Eaton Corp plc · HEAVY

ABS(ceo_total_comp) peer at $7.9M (Δ $20K lighter vs Vir Biotechnology, Inc.); MID · PAR-MED vs this page's FLOOR · HEAVY · ELITE-MED.
JBT MAREL Corp · HEAVY

ABS(ceo_total_comp) peer at $8.0M (Δ $29K heavier vs Vir Biotechnology, Inc.); MID · HIGH-MED vs this page's FLOOR · HEAVY · ELITE-MED.
Designer Brands Inc. · HEAVY

ABS(ceo_total_comp) peer at $7.9M (Δ $36K lighter vs Vir Biotechnology, Inc.); HIGH · LOW-MED vs this page's FLOOR · HEAVY · ELITE-MED.
Mirum Pharmaceuticals, Inc. (SIC 28 pole)

Mirum Pharmaceuticals, Inc. stamps FLOOR · HEAVY nearest in-SIC by ABS(pay_ratio) to Vir Biotechnology, Inc.'s FLOOR filing.
National dual ranks · #688/#1179

Vir Biotechnology, Inc.'s FY2025 package sits #688 by CEO dollars and #1179 by ratio under HEAVY · FLOOR.
Ratio primer · FLOOR

Vir Biotechnology, Inc.'s FLOOR stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Vir Biotechnology, Inc. (CIK 1706431), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.